KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Payables (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Payables data on record, last reported at $55.6 million in Q4 2025.

  • For Q4 2025, Payables fell 8.7% year-over-year to $55.6 million; the TTM value through Dec 2025 reached $55.6 million, down 8.7%, while the annual FY2025 figure was $55.6 million, 8.7% down from the prior year.
  • Payables reached $55.6 million in Q4 2025 per EBS's latest filing, down from $57.4 million in the prior quarter.
  • Across five years, Payables topped out at $1.1 billion in Q1 2023 and bottomed at $55.6 million in Q4 2025.
  • Average Payables over 5 years is $293.2 million, with a median of $149.7 million recorded in 2021.
  • Peak YoY movement for Payables: skyrocketed 673.87% in 2023, then plummeted 89.61% in 2025.
  • A 5-year view of Payables shows it stood at $160.5 million in 2021, then soared by 560.93% to $1.1 billion in 2022, then plummeted by 50.42% to $525.9 million in 2023, then tumbled by 88.42% to $60.9 million in 2024, then fell by 8.7% to $55.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $55.6 million in Q4 2025, $57.4 million in Q3 2025, and $63.7 million in Q2 2025.